Table 2 Community primary care physician (PCP) knowledge of OAC therapy in NVAF patients
Knowledge items | Frequency | Percentage % |
|---|---|---|
AF diagnosis | ||
No | 3 | 0.6 |
Yes | 494 | 99.4 |
Score tool for predicting stroke risk in AF patients | ||
No | 126 | 25.4 |
Yes | 371 | 74.6 |
Score tool for predicting bleeding risk in AF patients | ||
No | 220 | 44.3 |
Yes | 277 | 55.7 |
Risk factors included in the CHADS2 score | ||
No | 91 | 18.3 |
Yes | 406 | 81.7 |
Risk factors included in the CHADS2-VASc score | ||
No | 106 | 21.3 |
Yes | 391 | 78.7 |
Risk factors included the HAS-BLED score | ||
No | 181 | 36.4 |
Yes | 316 | 63.6 |
Which indicator should be monitored in AF patients with warfarin | ||
No | 17 | 3.4 |
Yes | 480 | 96.6 |
How long should be monitored coagulation function in AF patients with long-term warfarin therapy at a stable period? | ||
No | 377 | 75.9 |
Yes | 120 | 24.1 |
What’s the target range of INR in AF patients with warfarin under 75 years old | ||
No | 284 | 57.1 |
Yes | 213 | 42.9 |
What’s the target range of INR in AF patients with warfarin over 75 years old | ||
No | 270 | 54.3 |
Yes | 227 | 45.7 |
Which factor is susceptible to the anticoagulation effect of warfarin | ||
No | 47 | 9.5 |
Yes | 450 | 90.5 |
What’s the antagonist that antagonizes warfarin’s anticoagulation | ||
No | 29 | 5.8 |
Yes | 468 | 94.2 |
Which of the following AF patients need to adjust warfarin dose | ||
No | 164 | 33.0 |
Yes | 333 | 67.0 |
Which medication are the new oral anticoagulants (NOAC) | ||
No | 98 | 19.7 |
Yes | 399 | 80.3 |